Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – The nonhuman animal is a model for human disease
Reexamination Certificate
1995-06-02
2004-06-29
Priebe, Scott D. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
The nonhuman animal is a model for human disease
C424S093200, C514S04400A, C435S320100, C435S325000, C435S455000, C435S456000
Reexamination Certificate
active
06756523
ABSTRACT:
To transfer safely and efficiently therapeutic DNA into the central nervous system, is a formidable challenge in the development of active therapies in brain diseases.
Preliminary investigations have been carried out with a number of vectors, more particularly retroviral vectors and herpes simplex derived vectors. However the usefulness of such gene transfer vehicles has, to date, been limited.
In most cases, retroviral vectors are not useful because they are unable to infect postmitotic cells, including most neural cells (1). Herpes simplex derived vectors infect neural cells but problems of pathogenicity and of stability of gene expression remain unsolved (2,3). In addition Herpes simplex derived vectors have so far proven to have but limited efficacy of expression. In a most recent article (4) the authors refer to the short-term expression reported earlier of HSV-1 derived vectors, because most of the promoters used had only been active during the acute phase of viral infection (less than 10 days post-infection). They disclosed the expression of a b-glucuronidase gene in a cell of the central nervous system under the control of the LAT promoter normally associated with the latency-associated-transcript (LAT) sequence of the virus. But the authors also report that, even though their experiments demonstrated the feasibility of using the LAT promoter for long-term expression of foreign genes in cells of the central nervous system to correct a genetic enzymatic deficiency in infected cells, too few cells had been corrected to alter the disease phenotype. Consequently their vector system needed to be improved to correct sufficient cells for obtaining a clinically significant effect.
The invention aims at obviating such difficulties and at providing most effective vector systems capable of delivering foreign genes and, where appropriate, their transcription products or expression products directly to cells of the central nervous system, particularly to terminally differentiated cells, incapable of proliferation. A more particular object of the invention is also to allow for the wide spreading of such vector systems throughout the neural tissue to be infected, yet while remaining substantially confined thereto.
Still another object of the invention is to produce such vector systems which are sufficiently safe to allow for a study and regulation in vitro of cloned genes in such cells or in test animals, and for therapy, in man or animal, involving the in situ production of a selected expression product, including gene therapy.
The invention is based on the recognition that adenovirus-derived vectors, particularly non-replicative adenovirus vectors, are capable of fulfilling these aims, both in vitro and in vivo. They provide powerful delivery systems of genes into the cells of the central nervous system, more particularly brain cells. They are characterized by a degree of infectivity of sufficient magnitude to allow for the infection of considerable populations of cells. The biological experiments disclosed hereafter demonstrate the capability of adenovirus derived vectors (or adenoviral vectors) of efficiently infecting nerve cells, particularly neurons, both in vitro and in vivo.
Thus the invention provides a process for the production of a recombinant vector useful in a method comprising causing the transcription product or the expression product of a nucleotide sequence coding for a selected polypeptide to be targeted or produced in cells of the central nervous system, e.g. brain cells, particularly neural, glial or ependymal cells, wherein said recombinant vector is an adenoviral vector which comprises at least part of the genome of an adenovirus including those regions of that genome which provide the genetic information required by that adenovirus to penetrate into cells normally infectable by it, said nucleotide sequence being inserted in said genome part, under the control of a promoter either present or also inserted within said adenoviral vector, and said promoter being operative in said cells.
Thus the invention is more particularly related to the use of an adenovirus-derived vector for the expression of a selected nucleotide in the cells of the central nervous system.
The invention also provides a recombinant DNA vector characterized in that it is capable of directing the expression and/or transcription of a selected nucleotide sequence in the cells of the central nervous system and in that it comprises (i) at least part of the genome of an adenovirus, including the regions required for that adenovirus to penetrate into the cells of the central nervous system, and (ii) said selected nucleotide sequence under the control of a promoter operative in said cells.
REFERENCES:
patent: 4920209 (1990-04-01), Davis
patent: 5501979 (1996-03-01), Geller et al.
patent: 6245330 (2001-06-01), Horellou et al.
patent: 9005781 (1990-05-01), None
patent: 9104316 (1991-04-01), None
Braithwaite, “Semipermissive replication of adenovirus 5 in rqt brain cells and evidence for an induction of cellular DNA replication in vivo”, J. gen. Virol. 67: 391-396, 1986.*
Gluzman in Eukaryotic Viral Vectors, CSH, 1902, Oct. 20, 1997.*
Berkner in Current Topics in Microbiol & Immunol 158: 39, 1992, Oct. 20, 1997.*
Stratford-Perricaudet Human Gene Therapy 219: 51, 1991, Oct. 20, 1997.*
Rosenfeld Cell 68: 143, 1992, Oct. 20, 1997.*
Rojanasakul, Adv. Drug Del. Rev., 18:115-131, 1996.*
Friedmann, Trends in Genetics, 10(6) : 210-214, 1994.*
NIH “Report and Recommendations”. . . Dec. 7, 1995, p. 1-40.*
Marshall, E., Science, vol. 269, Aug. 1995 pp. 1050-1055.*
Gutierrez et al, The Lancet, vol. 339, Mar. 1992 pp. 715-721.*
Neve, R., Trends Neurosci, 16 (7), Jul. 1993 pp. 251-3.*
Wang et al, Adv. Exp. Med. Biol., 309 B, (Purine Pyr. Metab. Man. 7) 1991, pp. 61-66.*
Culver et al, Science, vol. 256, Jun. 1992 pp. 1550-2.*
Rosenfeld et al, Science, vol. 252, 1991 pp. 431-4.*
Federoff et al, Proc. Nat. Acad. Sci. vol. 89, Mar. 1992 pp. 1636-1640.*
Oellig et al, J. of Neuroscience Res. vol. 26, 1990, pp. 390-396.*
Geller et al, TINS, vol. 14, No. 10, 1991 pp. 428-432.*
Shea et al, J. of Neuroscience Res., vol. 32; 1992 pp. 363-374.*
Watson, “Recombination at the Molecular Level”, p. 313, Benjamin/Cumming Pub. Co. Inc., 1987.*
Cohen-Haguenal, Gene Therapy: Advances and Prospects, Pathologic et Biologie 40(1):5-13, 1992.
Babiss Friedman, Regulation of N-myc Gene Expression: Use of an Adeovirus Vector to, Molec. Cell Biol. 10(12): 6700-08, 1990.
Yang, Gene Transfer into Mammalian Somatic Cell In Vivo, Critical Reviews Biotech. 12(4): 335-56, 1992.
Irenaka, Nakahira, Nakajima, Fujimoto, Kagawa et al., Detection of Brain-Specific Gene Expression in Brain Cells in Primary Culture, New Biologist 4(1): 53-60, 1992.
Gage, Rosenberg, Wolff, Friedman, Grafting Genetically Modified Cells to Treat Diseases of the Central Nervous System., WO 90/06757 Dec. 12, 1989, Jun. 28, 1990.
Preston Ace, Herpes Simplex Virus Type 1 Mutant, WO 91/02788 Aug. 14, 1990, Mar. 7, 1991.
Geller, During, Wilcox, Federoff, Pardee et al., Cell Type Specific Alteration of Levels of Gene Products in Neural Cells, WO 92/07945 Oct 23, 1991, May 14, 1992.
Kahn Axel
Le Gal La Salle Gildas
Mallet Jacques
Perricaudet Michel
Peschanski Marc
Aventis Pharma S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Priebe Scott D.
LandOfFree
Adenovirus vectors for the transfer of foreign genes into... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenovirus vectors for the transfer of foreign genes into..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenovirus vectors for the transfer of foreign genes into... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3365468